Fusion Biopsy Market: Growth, Size, Share, and Trends

Report Code MD 9228
Published in Dec, 2024, By MarketsandMarkets™
Download PDF

Choose License Type

Buy Report Now Inquire Before Buying

Fusion Biopsy Market by Route Type (Transrectal, Transperineal), Product (Equipment, Consumables), Application (Prostate Cancer), End User (Hospitals), and Region - Global Forecast to 2029

Overview

The global fusion biopsy market, valued at US$0.61 billion in 2023, is forecasted to grow at a robust CAGR of 7.1%, reaching US$0.65 billion in 2024 and an impressive US$0.91 billion by 2029. Some main drivers for the growth of the fusion biopsy market are the growing prevalence of prostate cancer, since it's among one of the most common serious health concerns for males on a global scale. Fusion biopsy can be considered to be at the forefront in capitalizing on this demand for effective diagnostic solutions that are minimally invasive, as this can couple MRI and ultrasound imaging together for precise targeting of suspicious-appearing lesions.

Fusion Biopsy Market – Global Forecast and Key Opportunities to 2029

Attractive Opportunities in the Fusion Biopsy Market

Asia Pacific

Growth in the Asia Pacific market can be attributed to the presence of a large patient population, improving public health awareness (leading to rising awareness regarding cancer), and increasing healthcare investments

The growth of this market can be attributed to the growing healthcare infrastructure and increasing cases prostate cancer and growing geriatric population.

Emerging markets are expected to offer significant growth opportunities for players operating in the fusion biopsy market.

The Asia Pacific market is projected to hold the highest CAGR.

The global fusion biopsy market is projected to reach USD 0.91 billion by 2029 from USD 0.65 billion in 2024, at a CAGR of 7.1%.

Global Fusion Biopsy Market Dynamics

DRIVER: Rising prevalence of minimally invasive surgery

The rising prevalence of minimally invasive surgery is a key driver for the fusion biopsy market, as it aligns with the growing patient preference for procedures that offer reduced pain, faster recovery, and fewer complications. Minimally invasive prostate resection is surgery to remove part of the prostate gland, to treat an enlarged prostate. Traditionally, open surgical biopsy was considered a benchmark procedure to screen and diagnose abnormalities. However, during the last few decades, a new understanding of cancers such as prostate cancer, breast cancer, liver cancer, etc. has emerged, leading to open biopsies being replaced by minimally invasive procedures. It has contributed to a paradigm shift in the diagnosis of these cancers, and the use of image-guided, minimally invasive techniques such as fusion biopsy has flourished. Minimally invasive procedures provide increased patient comfort, minimal blood loss and trauma, limited scarring, fewer operative complications, and less postoperative care. They also tend to be less expensive relative to open surgical biopsies. As a result of these advantages, minimally invasive biopsies have enjoyed remarkable demand globally, a factor that influences the fusion biopsy market

RESTRAINT: High cost of fusion biopsy system

The high price of these fusion biopsy systems is considered to be one of the major constraints on the market, particularly in price-sensitive regions and smaller healthcare facilities. Advanced fusion biopsy systems that integrate high-end MRI and ultrasound technologies typically require significant equipment and maintenance investments and specialized training for operators. This financial burden can limit adoption, especially in low- and middle-income countries where healthcare budgets are constrained. Most hospitals in developing countries cannot afford diagnostic imaging systems owing to their high cost. Prostate cancer is the second leading cause of cancer deaths among men, and the American Cancer Society predicts that one in seven men will be diagnosed with prostate cancer during their lifetime.

This is further compounded by the requirement of pre-procedure imaging, normally in the form of MRI scans, which makes access quite impossible for a large chunk of the population because of cost-sensitive regions. The high cost becomes a critical financial barrier, especially within an environment like public health, where the budget is usually constrained. The issue of reimbursement itself, even in developed markets, may be a limiting factor in the wide diffusion of these systems, as many insurance providers simply will not fully reimburse for the procedure or associated imaging costs.

 

OPPORTUNITY: Technological advancements in fusion biopsy devices

The fusion biopsy market participants have enormous growth opportunities due to the emerging developments in the field. Such invention developments, iteratively carried out, encompass but are not restricted to better MRI-ultrasound fusion platforms, image registration algorithms, integration of AI with lesion detection and biopsy targeting, among others, that are shape-shifting diagnostics with significantly improved accuracy. Advanced systems employing elastic registration, real-time 3D navigation, and robotic-assisted guidance can result in more accurate targeting of suspicious lesions, particularly when such lesions positioned in difficult or very small regions.

However, the integration of AI and ML in fusion biopsy technology will open up new avenues for growth among market participants. The algorithms of AI and ML improve lesion detection and classification based on MRI and ultrasound images with heightened clarity, thus leading clinicians to further investigate areas that raise suspicion for biopsy. This improves diagnostic precision and reduces the likelihood that clinically significant cancer diagnoses will be overlooked by clinicians. Additional integration of real-time 3D deformable image registration algorithms may enable the accuracy of MRI/US fusion, thus increasing the outcomes in biopsies and further giving a fillip to market growth.

CHALLENGES: Limited reimbursement in few countries

The greater challenge for the growth of the fusion biopsy market remains limited reimbursement, especially in some countries, since it is directly related to the affordability and accessibility of these advanced diagnostic procedures. Increasing awareness of various types of cancers means that, over the next few years, biopsy procedures are likely to be in demand in developing economies. Due to limited healthcare resources and underdeveloped infrastructure, alternative strategies for the diagnosis of prostate cancer are widely used in the region. Mortality caused by cancer is also higher in low- and middle-income countries as compared to high-income countries; this is mainly due to the lack of early detection in these countries.

High costs primarily dissuade patients from undergoing the whole fusion biopsy procedure in those regions where insurance coverage is either minimal or simply absent. In most developing markets, and even some developed ones, the lack of reimbursement policies to suitably cover the cost of advanced imaging techniques such as MRI or the exclusion of costs related to fusion biopsy systems and consumables is highly evident. In addition to constraining growth, the lack of comprehensive reimbursement exacerbates disparities in access to advanced diagnostic solutions across different geographies.

Global Fusion Biopsy Market Ecosystem Analysis

The fusion biopsy market ecosystem includes manufacturers, distributors, and end users of fusion biopsy systems. The key manufacturers of fusion biopsy products are Eigen Health (US), GE Healthcare (US), Koninklijke Philips N.V. (Netherlands), Esaote SPA (Italy), KOELIS (France), FUJIFILM Holdings Corporation (Japan), MTT GMBH (Germany), Focal Healthcare (Canada). Agiliti Health, Inc. (US), Kebomed Europe AG (UK), innoMedicus (Switzerland) are among the few distributors in the fusion biopsy market. However, Mount Sinai (US), Heidelberg University Hospital (Germany), and Mayo Clinic (US) are few of the end users in the market.

Fusion Biopsy Market
 

By route type, the transperineal segment is projected to register the highest CAGR in the forecasted period.

The fusion biopsy market is divided into transrectal, transperineal, and other route types. Transperineal method is reported to provide more comprehensive sampling of the entire prostate, with advocates highlighting a potentially reduced risk of post-biopsy sepsis. In the case of a transperineal biopsy, the urologist inserts the biopsy needle through skin in the perineum into the prostate, bypassing the rectum and reducing the risk of contamination. An ultrasound probe positioned in the rectum guides the procedure to ensure appropriate placement of the needle and effective tissue sampling.

Furtehr, this high growth can be attributed to the increasing adoption of transperineal biopsy techniques due to their superior accuracy in the sampling of the prostate, especially areas around the anterior and apical regions missed in the trans-rectal approaches. The transperineal route of administration also offers a much-reduced risk of infection, such as sepsis, by avoiding the flora of the rectum and thus is safer for the patients. This has been significantly facilitated by advances in needle guidance systems and imaging technologies for enhanced precision, ease of use, and physician awareness and training. Due to such advantages, the transperineal segment will result in wide-scale adoption at an overarching growth rate globally.

By product, the equipment segment has the largest market share in 2023 and is projected to have highest CAGR during the forecast period.

The fusion biopsy market is divided into equipment and consumables based on product segment. The high adoption of technologically advanced equipment, especially in developed regions, reflects the increasing preference for minimally invasive diagnostic solutions. Further development in the field of imaging technologies, along with the inclusion of AI, increased demand to such an extent that it consolidated the lead of the equipment segment in this domain.

Fusion biopsy represents a revolutionary technology that fuses ultrasound imaging with MRI sequences, thus enabling better visualization and more precise targeting of prostate lesions. Special equipment overlays MRI-detected suspect areas onto real-time ultrasound images, enabling urologists to target and take biopsies much more precisely. For instance, Philips UroNav is an example of a fusion biopsy system, which combines pre-biopsy MRI images of the prostate with real-time ultrasound-guided biopsy images and achieve outstanding delineation of the prostate with suspicious lesions.

However, growing awareness about the various benefits of fusion biopsy to ensure accurate diagnosis of prostate cancer, coupled with rising investments in health care, is expected to accelerate adoption of fusion biopsy systems during the forecast period.

In 2023, Europe accounted for the largest share of the fusion biopsy market, followed by North America, by region

The global fusion biopsy market is segmented into six major regions namely, North America, Europe, the Asia Pacific, Middle East & Africa, Latin America, and the GCC Countries.In 2023, Europe continued to be the major fusion biopsy market due to its well-developed healthcare infrastructure and increased adoption of advanced diagnostic technologies because of general awareness about the importance of cancer screening programs. Favorable reimbursement policies along with supportive government initiatives in this regard promote early detection and hence boost the market in the region. Health care costs in Europe increased exponentially and different initiatives taken to raise funds to cover the health care cost proved insufficient. Besides, the largest share was contributed by Germany among the European market. Some of the reasons contributing to its significant share of market growth include robust healthcare spending of the country, increasing per capita disposable income, and favorable government investments.

However, North America is holds second largest share of fusion biopsy market in 2023. Its advanced healthcare infrastructure, high prostate cancer incidence, and strong presence of leading companies driving innovation contribute significantly to the market growth.

HIGHEST CAGR MARKET IN 2023
GERMANY FASTEST GROWING MARKET IN THE REGION
Fusion Biopsy Market

Recent Developments of Fusion Biopsy Market

  • FUJIFILM Healthcare announced, effective April 6th, 2023, the release of the new ARIETTA 65 IntuitiveFusion, an MRI-Ultrasound fusion system extending its engineering process to help further enhance efficiency during prostate biopsies. With improved precision, it will enhance prostate biopsy procedures in a seamless way.
  • September 2023: Koelis DeepHealth has announced a partnership that will see users of the Koelis Trinity 3D Ultrasound Platform have access to DeepHealth's Prostate AI software for efficient interpretation of the prostate MRI and guidance of prostate fusion biopsies.

Key Market Players

KEY PLAYERS IN THE FUSION BIOPSY MARKET INCLUDE

Want to explore hidden markets that can drive new revenue in Fusion Biopsy Market?

Scope of the Report

Report Metric Details
Market size available for years 2022-2029
Base Year Considered 2023
Forecast period 2024-2029
Forecast units Value (USD Billion)
Segments covered Route type, Product, Application, End User, and Region
Geographies covered North America, Europe, Asia Pacific, Middle East & Africa, Latin America, and the GCC Countries

 

Key Questions Addressed by the Report

What are the driving factors of the fusion biopsy market?
The driving factors include the increasing prostate cancer population along with growing older population, increasing prevalence of minimally invasive procedures, and growing availability of reimbursement policies and investemnets are among the others.
How big is the fusion biopsy market worldwide?
As the fusion biopsy market grows at a CAGR of 7.1% over the forecast period, it is expected to reach USD 0.91 billion by 2029 from USD 0.65 billion in 2024.
Which product categories does fusion biopsy cover? Which product category does the leader belong to?
By product type, global fusion biopsy market was categorized into two segments: equipment and consumables. In 2023, the equipment segment dominated the fusion biopsy market. With continuous development in the field of imaging technologies and integration of AI leading to solidification, the equipment segment dominated the market.
Which type of route is dominating in the fusion biopsy market in 2023?
Route type segment: The transrectal, transperineal, and other route types are included. Transrectal route dominated the segment share in the year 2023, due to the established usage in prostate cancer diagnostic applications.
Who are the end users of the fusion biopsy systems? Which end-user is dominating the market?
The fusion biopsy market is segmented into hospitals and other end users. Other end user comprises of ambulatory surgery centers (ASCs) and cancer centers. This is because the hospital segment accounted for the largest share of the fusion biopsy market in 2023, primarily because the setting up of fusion biopsy techniques requires extensive infrastructure, the latest imaging technologies, and a skilled manpower that is usually available in hospitals.
Who are the key players in the fusion biopsy market? Who are the key players in the fusion biopsy market?
The key players in the fusion biopsy market are Koninklijke Philips N.V. (Netherlands), GE HealthCare (US), KOELIS (France), FUJIFILM Holdings Corporation (Japan), Eigen Health (US), Focal Healthcare (Canada), Esaote SPA (Italy), MTT GmbH (Germany), Canon Inc. (Japan), Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (China), MedCom (Germany), UC-Care Medical Systems (US), and Biobot Surgical (Singapore).
Which region is lucrative for the fusion biopsy market?
The Asia Pacific market is expected to witness the highest growth during the forecast period. The Asia Pacific market is expected to witness the highest growth during the forecast period due to the rising prevalence of cancer, increasing awareness of early diagnostic techniques, and improving healthcare infrastructure in emerging economies like China, India.

 

Personalize This Research

  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
Request A Free Customisation

Let Us Help You

  • What are the Known and Unknown Adjacencies Impacting the Fusion Biopsy Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
Customized Workshop Request

Table Of Contents

Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.

TITLE
PAGE NO
INTRODUCTION
20
RESEARCH METHODOLOGY
24
EXECUTIVE SUMMARY
39
PREMIUM INSIGHTS
43
MARKET OVERVIEW
46
  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    DRIVERS
    - Increasing prevalence of prostate cancer and growing geriatric population
    - Availability of reimbursements and investments by public and private sectors
    - Rising prevalence of minimally invasive surgery
    RESTRAINTS
    - High costs of fusion biopsy systems
    - Alternative methods for fusion biopsy
    OPPORTUNITIES
    - Rise in prevalence of prostate cancer in emerging economies
    - Technological advancements in fusion biopsy devices
    CHALLENGES
    - Paucity of skilled professionals
    - Limited reimbursement in few countries
  • 5.3 PRICING ANALYSIS
    PRICING ANALYSIS, BY REGION
    PRICING ANALYSIS, BY PRODUCT
  • 5.4 VALUE CHAIN ANALYSIS
  • 5.5 SUPPLY CHAIN ANALYSIS
  • 5.6 ECOSYSTEM ANALYSIS
    FUSION BIOPSY MARKET: ROLE OF COMPANIES IN ECOSYSTEM
  • 5.7 PORTER’S FIVE FORCES ANALYSIS
    THREAT OF NEW ENTRANTS
    THREAT OF SUBSTITUTES
    BARGAINING POWER OF BUYERS
    BARGAINING POWER OF SUPPLIERS
    INTENSITY OF COMPETITIVE RIVALRY
  • 5.8 KEY STAKEHOLDERS AND BUYING CRITERIA
    KEY STAKEHOLDERS IN BUYING PROCESS
    BUYING CRITERIA
  • 5.9 REGULATORY LANDSCAPE
    NORTH AMERICA
    - US
    - Canada
    EUROPE
    ASIA PACIFIC
    - Japan
    - China
    - India
    LATIN AMERICA
    - BRAZIL
    - MEXICO
    MIDDLE EAST
    AFRICA
    LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.10 TRADE ANALYSIS
    TRADE ANALYSIS FOR FUSION BIOPSY MARKET
  • 5.11 PATENT ANALYSIS
  • 5.12 KEY CONFERENCES AND EVENTS IN 2024–2026
  • 5.13 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
  • 5.14 TECHNOLOGY ANALYSIS
    KEY TECHNOLOGIES
    - MRI-ultrasound fusion imaging
    COMPLEMENTARY TECHNOLOGIES
    - Liquid biopsy
  • 5.15 INVESTMENT & FUNDING SCENARIO
  • 5.16 IMPACT OF GENERATIVE ARTIFICIAL INTELLIGENCE ON FUSION BIOPSY MARKET
FUSION BIOPSY MARKET, BY ROUTE TYPE
75
  • 6.1 INTRODUCTION
  • 6.2 TRANSRECTAL
    HEIGHTENED POTENTIAL FOR SERIOUS INFECTIONS TO HINDER MARKET GROWTH
  • 6.3 TRANSPERINEAL
    IMPROVED CANCER DETECTION THROUGH COMBINATION OF MRI AND ULTRASOUND TO FUEL MARKET GROWTH
  • 6.4 OTHER ROUTE TYPES
FUSION BIOPSY MARKET, BY APPLICATION
83
  • 7.1 INTRODUCTION
  • 7.2 PROSTATE CANCER
    PRECISE AND RELIABLE RESULTS OF PROSTATE FUSION BIOPSY TO ACCELERATE MARKET GROWTH
  • 7.3 OTHER APPLICATIONS
FUSION BIOPSY MARKET, BY PRODUCT
89
  • 8.1 INTRODUCTION
  • 8.2 EQUIPMENT
    SUBSTANTIAL INITIAL INVESTMENTS TO ENSURE MARKET GROWTH
  • 8.3 CONSUMABLES
    INCREASING APPLICATION OF INNOVATIVE TECHNOLOGIES AND METHODOLOGIES TO PROPEL MARKET GROWTH
FUSION BIOPSY MARKET, BY END USER
96
  • 9.1 INTRODUCTION
  • 9.2 HOSPITALS
    RISING DEMAND FOR QUICK AND ACCURATE DIAGNOSIS TO PROMOTE MARKET GROWTH
  • 9.3 OTHER END USERS
FUSION BIOPSY MARKET, BY REGION
102
  • 10.1 INTRODUCTION
  • 10.2 NORTH AMERICA
    MACROECONOMIC OUTLOOK FOR NORTH AMERICA
    US
    - Funding for cancer research and availability of technologically advanced products to propel market growth
    CANADA
    - Surging need for advanced diagnostic solutions to drive market
  • 10.3 EUROPE
    MACROECONOMIC OUTLOOK FOR EUROPE
    GERMANY
    - Rising healthcare expenditure and increasing incidence of cancer to bolster market growth
    UK
    - Enhanced clinical infrastructure to accelerate fusion biopsy adoption
    FRANCE
    - Effective reimbursement policies and government support for surgical product manufacturers to augment market
    ITALY
    - Rising healthcare demands of geriatric population to support market growth
    SPAIN
    - Improved healthcare infrastructure and rising geriatric demographics to boost market
    REST OF EUROPE
  • 10.4 ASIA PACIFIC
    MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
    CHINA
    - Increasing disposable income of middle-class population and rising diagnostic procedures to boost market
    JAPAN
    - Robust healthcare system and surging need for precise early cancer detection to support market growth
    INDIA
    - Large patient population and increasing healthcare investments to drive market
    REST OF ASIA PACIFIC
  • 10.5 LATIN AMERICA
    LOW FOCUS ON INFRASTRUCTURAL IMPROVEMENT AND POOR DISTRIBUTION OF RESOURCES LIKELY TO HINDER MARKET GROWTH
    MACROECONOMIC OUTLOOK FOR LATIN AMERICA & CARIBBEAN
  • 10.6 MIDDLE EAST & AFRICA
    EXPANDING ACCESS TO HEALTHCARE AND INCREASED HEALTHCARE INVESTMENTS TO PROPEL MARKET
    MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
  • 10.7 GCC COUNTRIES
    ADVANCEMENTS AND INCREASED GOVERNMENT INVESTMENTS IN HEALTHCARE SECTOR TO PROPEL MARKET
    MACROECONOMIC OUTLOOK FOR GCC COUNTRIES
COMPETITIVE LANDSCAPE
150
  • 11.1 OVERVIEW
  • 11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
    OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN FUSION BIOPSY MARKET
  • 11.3 REVENUE SHARE ANALYSIS, 2021–2023
  • 11.4 MARKET SHARE ANALYSIS, 2023
  • 11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
    STARS
    EMERGING LEADERS
    PERVASIVE PLAYERS
    PARTICIPANTS
    COMPANY FOOTPRINT: KEY PLAYERS, 2023
    - Company footprint
    - Region footprint
    - Route type footprint
    - Product footprint
    - Application footprint
    - End user footprint
  • 11.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
    PROGRESSIVE COMPANIES
    STARTING BLOCKS
    RESPONSIVE COMPANIES
    DYNAMIC COMPANIES
    COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
  • 11.7 COMPANY VALUATION & FINANCIAL METRICS, 2024
  • 11.8 BRAND/PRODUCT COMPARISON
  • 11.9 COMPETITIVE SCENARIO
    PRODUCT LAUNCHES & APPROVALS
    DEALS
COMPANY PROFILES
166
  • 12.1 KEY PLAYERS
    KONINKLIJKE PHILIPS N.V.
    - Business overview
    - Products offered
    - MnM view
    GE HEALTHCARE
    - Business overview
    - Products offered
    - MnM view
    KOELIS
    - Business overview
    - Products offered
    - Recent developments
    - MnM view
    FUJIFILM HOLDINGS CORPORATION
    - Business overview
    - Products offered
    - Recent developments
    CANON INC.
    - Business overview
    - Products offered
    SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.
    - Business overview
    - Products offered
    ESAOTE SPA
    - Business overview
    - Products offered
    EIGEN HEALTH
    - Business overview
    - Products offered
  • 12.2 OTHER PLAYERS
    FOCAL HEALTHCARE
    MTT GMBH
    MEDCOM
    UC-CARE MEDICAL SYSTEMS
    BIOBOT SURGICAL
APPENDIX
188
  • 13.1 DISCUSSION GUIDE
  • 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
  • 13.3 CUSTOMIZATION OPTIONS
  • 13.4 RELATED REPORTS
  • 13.5 AUTHOR DETAILS
LIST OF TABLES
 
  • TABLE 1 RISK ASSESSMENT
  • TABLE 2 PROSTATE CANCER INCIDENCE, BY REGION, 2022
  • TABLE 3 AVERAGE SELLING PRICE TREND OF FUSION BIOPSY PRODUCTS, BY REGION, 2021–2023
  • TABLE 4 PRICING ANALYSIS OF FUSION BIOPSY PRODUCTS, 2021–2023
  • TABLE 5 FUSION BIOPSY MARKET: PORTER’S FIVE FORCES ANALYSIS
  • TABLE 6 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF FUSION BIOPSY END USERS (%)
  • TABLE 7 KEY BUYING CRITERIA FOR FUSION BIOPSY END USERS
  • TABLE 8 US FDA: MEDICAL DEVICE CLASSIFICATION
  • TABLE 9 US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS
  • TABLE 10 CANADA: MEDICAL DEVICE REGULATORY APPROVAL PROCESS
  • TABLE 11 JAPAN: MEDICAL DEVICE CLASSIFICATION UNDER PMDA
  • TABLE 12 CHINA: CLASSIFICATION OF MEDICAL DEVICES
  • TABLE 13 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 14 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 15 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 16 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 17 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 18 IMPORT DATA FOR FUSION BIOPSY MARKET, BY COUNTRY, 2019–2023 (USD MILLION)
  • TABLE 19 EXPORT DATA FOR FUSION BIOPSY MARKET, BY COUNTRY, 2019–2023 (USD MILLION)
  • TABLE 20 FUSION BIOPSY MARKET: KEY CONFERENCES AND EVENTS IN 2024–2026
  • TABLE 21 FUSION BIOPSY MARKET, BY ROUTE TYPE, 2022–2029 (USD MILLION)
  • TABLE 22 FUSION BIOPSY MARKET FOR TRANSRECTAL ROUTE TYPES, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 23 NORTH AMERICA: FUSION BIOPSY MARKET FOR TRANSRECTAL ROUTE TYPES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 24 EUROPE: FUSION BIOPSY MARKET FOR TRANSRECTAL ROUTE TYPES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 25 ASIA PACIFIC: FUSION BIOPSY MARKET FOR TRANSRECTAL ROUTE TYPES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 26 FUSION BIOPSY MARKET FOR TRANSPERINEAL ROUTE TYPES, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 27 NORTH AMERICA: FUSION BIOPSY MARKET FOR TRANSPERINEAL ROUTE TYPES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 28 EUROPE: FUSION BIOPSY MARKET FOR TRANSPERINEAL ROUTE TYPES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 29 ASIA PACIFIC: FUSION BIOPSY MARKET FOR TRANSPERINEAL ROUTE TYPES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 30 FUSION BIOPSY MARKET FOR OTHER ROUTE TYPES, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 31 NORTH AMERICA: FUSION BIOPSY MARKET FOR OTHER ROUTE TYPES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 32 EUROPE: FUSION BIOPSY MARKET FOR OTHER ROUTE TYPES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 33 ASIA PACIFIC: FUSION BIOPSY MARKET FOR OTHER ROUTE TYPES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 34 FUSION BIOPSY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 35 PROSTATE CANCER INCIDENCE, BY REGION, 2022
  • TABLE 36 FUSION BIOPSY MARKET FOR PROSTATE CANCER, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 37 NORTH AMERICA: FUSION BIOPSY MARKET FOR PROSTATE CANCER, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 38 EUROPE: FUSION BIOPSY MARKET FOR PROSTATE CANCER, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 39 ASIA PACIFIC: FUSION BIOPSY MARKET FOR PROSTATE CANCER, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 40 FUSION BIOPSY MARKET FOR OTHER APPLICATIONS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 41 NORTH AMERICA: FUSION BIOPSY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 42 EUROPE: FUSION BIOPSY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 43 ASIA PACIFIC: FUSION BIOPSY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 44 FUSION BIOPSY MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 45 KEY PRODUCTS IN FUSION BIOPSY EQUIPMENT MARKET
  • TABLE 46 FUSION BIOPSY MARKET FOR EQUIPMENT, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 47 NORTH AMERICA: FUSION BIOPSY MARKET FOR EQUIPMENT, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 48 EUROPE: FUSION BIOPSY MARKET FOR EQUIPMENT, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 49 ASIA PACIFIC: FUSION BIOPSY MARKET FOR EQUIPMENT, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 50 KEY PRODUCTS IN FUSION BIOPSY CONSUMABLES MARKET
  • TABLE 51 FUSION BIOPSY MARKET FOR CONSUMABLES, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 52 NORTH AMERICA: FUSION BIOPSY MARKET FOR CONSUMABLES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 53 EUROPE: FUSION BIOPSY MARKET FOR CONSUMABLES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 54 ASIA PACIFIC: FUSION BIOPSY MARKET FOR CONSUMABLES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 55 FUSION BIOPSY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 56 FUSION BIOPSY MARKET FOR HOSPITALS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 57 NORTH AMERICA: FUSION BIOPSY MARKET FOR HOSPITALS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 58 EUROPE: FUSION BIOPSY MARKET FOR HOSPITALS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 59 ASIA PACIFIC: FUSION BIOPSY MARKET FOR HOSPITALS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 60 FUSION BIOPSY MARKET FOR OTHER END USERS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 61 NORTH AMERICA: FUSION BIOPSY MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 62 EUROPE: FUSION BIOPSY MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 63 ASIA PACIFIC: FUSION BIOPSY MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 64 FUSION BIOPSY MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 65 NORTH AMERICA: PROSTATE CANCER INCIDENCE, BY COUNTRY, 2022
  • TABLE 66 NORTH AMERICA: MACROECONOMIC OUTLOOK
  • TABLE 67 NORTH AMERICA: FUSION BIOPSY MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 68 NORTH AMERICA: FUSION BIOPSY MARKET, BY ROUTE TYPE, 2022–2029 (USD MILLION)
  • TABLE 69 NORTH AMERICA: FUSION BIOPSY MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 70 NORTH AMERICA: FUSION BIOPSY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 71 NORTH AMERICA: FUSION BIOPSY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 72 US: NUMBER OF MAGNETIC RESONANCE IMAGING (MRI) EXAMS CONDUCTED, 2022–2029 (NUMBER PER 1,000 PERSONS)
  • TABLE 73 US: FUSION BIOPSY MARKET, BY ROUTE TYPE, 2022–2029 (USD MILLION)
  • TABLE 74 US: FUSION BIOPSY MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 75 US: FUSION BIOPSY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 76 US: FUSION BIOPSY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 77 CANADA: FUSION BIOPSY MARKET, BY ROUTE TYPE, 2022–2029 (USD MILLION)
  • TABLE 78 CANADA: FUSION BIOPSY MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 79 CANADA: FUSION BIOPSY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 80 CANADA: FUSION BIOPSY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 81 EUROPE: CANCER INCIDENCE, MORTALITY, AND PREVALENCE, BY CANCER TYPE, 2022
  • TABLE 82 EUROPE: MACROECONOMIC OUTLOOK
  • TABLE 83 EUROPE: FUSION BIOPSY MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 84 EUROPE: FUSION BIOPSY MARKET, BY ROUTE TYPE, 2022–2029 (USD MILLION)
  • TABLE 85 EUROPE: FUSION BIOPSY MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 86 EUROPE: FUSION BIOPSY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 87 EUROPE: FUSION BIOPSY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 88 GERMANY: CANCER INCIDENCE, MORTALITY, AND PREVALENCE, BY CANCER TYPE, 2022
  • TABLE 89 GERMANY: NUMBER OF MAGNETIC RESONANCE IMAGING (MRI) EXAMS CONDUCTED, 2022–2029 (NUMBER PER 1,000 PERSONS)
  • TABLE 90 GERMANY: FUSION BIOPSY MARKET, BY ROUTE TYPE, 2022–2029 (USD MILLION)
  • TABLE 91 GERMANY: FUSION BIOPSY MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 92 GERMANY: FUSION BIOPSY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 93 GERMANY: FUSION BIOPSY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 94 UK: CANCER INCIDENCE, MORTALITY, AND PREVALENCE, BY CANCER TYPE, 2022
  • TABLE 95 UK: FUSION BIOPSY MARKET, BY ROUTE TYPE, 2022–2029 (USD MILLION)
  • TABLE 96 UK: FUSION BIOPSY MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 97 UK: FUSION BIOPSY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 98 UK: FUSION BIOPSY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 99 FRANCE: CANCER INCIDENCE, MORTALITY, AND PREVALENCE, BY CANCER TYPE, 2022
  • TABLE 100 FRANCE: FUSION BIOPSY MARKET, BY ROUTE TYPE, 2022–2029 (USD MILLION)
  • TABLE 101 FRANCE: FUSION BIOPSY MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 102 FRANCE: FUSION BIOPSY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 103 FRANCE: FUSION BIOPSY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 104 ITALY: CANCER INCIDENCE, MORTALITY, AND PREVALENCE, BY CANCER TYPE, 2022
  • TABLE 105 ITALY: FUSION BIOPSY MARKET, BY ROUTE TYPE, 2022–2029 (USD MILLION)
  • TABLE 106 ITALY: FUSION BIOPSY MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 107 ITALY: FUSION BIOPSY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 108 ITALY: FUSION BIOPSY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 109 SPAIN: CANCER INCIDENCE, MORTALITY, AND PREVALENCE, BY CANCER TYPE, 2022
  • TABLE 110 SPAIN: FUSION BIOPSY MARKET, BY ROUTE TYPE, 2022–2029 (USD MILLION)
  • TABLE 111 SPAIN: FUSION BIOPSY MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 112 SPAIN: FUSION BIOPSY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 113 SPAIN: FUSION BIOPSY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 114 REST OF EUROPE: PROSTATE CANCER INCIDENCE, BY COUNTRY, 2022
  • TABLE 115 REST OF EUROPE: FUSION BIOPSY MARKET, BY ROUTE TYPE, 2022–2029 (USD MILLION)
  • TABLE 116 REST OF EUROPE: FUSION BIOPSY MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 117 REST OF EUROPE: FUSION BIOPSY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 118 REST OF EUROPE: FUSION BIOPSY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 119 ASIA PACIFIC: MACROECONOMIC OUTLOOK
  • TABLE 120 ASIA PACIFIC: FUSION BIOPSY MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 121 ASIA PACIFIC: FUSION BIOPSY MARKET, BY ROUTE TYPE, 2022–2029 (USD MILLION)
  • TABLE 122 ASIA PACIFIC: FUSION BIOPSY MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 123 ASIA PACIFIC: FUSION BIOPSY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 124 ASIA PACIFIC: FUSION BIOPSY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 125 CHINA: CANCER INCIDENCE, BY TYPE, 2022 VS. 2030
  • TABLE 126 CHINA: FUSION BIOPSY MARKET, BY ROUTE TYPE, 2022–2029 (USD MILLION)
  • TABLE 127 CHINA: FUSION BIOPSY MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 128 CHINA: FUSION BIOPSY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 129 CHINA: FUSION BIOPSY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 130 JAPAN: CANCER INCIDENCE, BY TYPE, 2022 VS. 2030
  • TABLE 131 JAPAN: FUSION BIOPSY MARKET, BY ROUTE TYPE, 2022–2029 (USD MILLION)
  • TABLE 132 JAPAN: FUSION BIOPSY MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 133 JAPAN: FUSION BIOPSY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 134 JAPAN: FUSION BIOPSY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 135 INDIA: CANCER INCIDENCE, BY TYPE, 2022 VS. 2030
  • TABLE 136 INDIA: FUSION BIOPSY MARKET, BY ROUTE TYPE, 2022–2029 (USD MILLION)
  • TABLE 137 INDIA: FUSION BIOPSY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 138 INDIA: FUSION BIOPSY MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 139 INDIA: FUSION BIOPSY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 140 PROSTATE CANCER INCIDENCE, BY COUNTRY, 2022 VS. 2030
  • TABLE 141 REST OF ASIA PACIFIC: FUSION BIOPSY MARKET, BY ROUTE TYPE, 2022–2029 (USD MILLION)
  • TABLE 142 REST OF ASIA PACIFIC: FUSION BIOPSY MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 143 REST OF ASIA PACIFIC: FUSION BIOPSY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 144 REST OF ASIA PACIFIC: FUSION BIOPSY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 145 LATIN AMERICA: PROSTATE CANCER INCIDENCE, 2022
  • TABLE 146 LATIN AMERICA & CARIBBEAN: MACROECONOMIC OUTLOOK
  • TABLE 147 LATIN AMERICA: FUSION BIOPSY MARKET, BY ROUTE TYPE, 2022–2029 (USD MILLION)
  • TABLE 148 LATIN AMERICA: FUSION BIOPSY MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 149 LATIN AMERICA: FUSION BIOPSY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 150 LATIN AMERICA: FUSION BIOPSY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 151 AFRICA: CANCER INCIDENCE, MORTALITY, AND PREVALENCE, BY CANCER TYPE, 2022
  • TABLE 152 MIDDLE EAST & AFRICA: MACROECONOMIC OUTLOOK
  • TABLE 153 MIDDLE EAST & AFRICA: FUSION BIOPSY MARKET, BY ROUTE TYPE, 2022–2029 (USD MILLION)
  • TABLE 154 MIDDLE EAST & AFRICA: FUSION BIOPSY MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 155 MIDDLE EAST & AFRICA: FUSION BIOPSY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 156 MIDDLE EAST & AFRICA: FUSION BIOPSY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 157 GCC COUNTRIES: MACROECONOMIC OUTLOOK
  • TABLE 158 GCC COUNTRIES: FUSION BIOPSY MARKET, BY ROUTE TYPE, 2022–2029 (USD MILLION)
  • TABLE 159 GCC COUNTRIES: FUSION BIOPSY MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 160 GCC COUNTRIES: FUSION BIOPSY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 161 GCC COUNTRIES: FUSION BIOPSY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 162 OVERVIEW OF STRATEGIES ADOPTED BY KEY MARKET PLAYERS
  • TABLE 163 FUSION BIOPSY MARKET: DEGREE OF COMPETITION
  • TABLE 164 FUSION BIOPSY MARKET: COMPANY FOOTPRINT
  • TABLE 165 FUSION BIOPSY MARKET: REGION FOOTPRINT
  • TABLE 166 FUSION BIOPSY MARKET: ROUTE TYPE FOOTPRINT
  • TABLE 167 FUSION BIOPSY MARKET: PRODUCT FOOTPRINT
  • TABLE 168 FUSION BIOPSY MARKET: APPLICATION FOOTPRINT
  • TABLE 169 FUSION BIOPSY MARKET: END USER FOOTPRINT
  • TABLE 170 FUSION BIOPSY MARKET: DETAILED LIST OF KEY STARTUPS/SME PLAYERS
  • TABLE 171 FUSION BIOPSY MARKET: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS
  • TABLE 172 FUSION BIOPSY MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–MARCH 2024
  • TABLE 173 FUSION BIOPSY MARKET: DEALS, JANUARY 2021–MARCH 2024
  • TABLE 174 KONINKLIJKE PHILIPS N.V.: BUSINESS OVERVIEW
  • TABLE 175 KONINKLIJKE PHILIPS N.V.: PRODUCTS OFFERED
  • TABLE 176 GE HEALTHCARE: BUSINESS OVERVIEW
  • TABLE 177 GE HEALTHCARE: PRODUCTS OFFERED
  • TABLE 178 KOELIS: BUSINESS OVERVIEW
  • TABLE 179 KOELIS: PRODUCT OFFERED
  • TABLE 180 KOELIS: DEALS, JANUARY 2021–MARCH 2024
  • TABLE 181 FUJIFILM HOLDINGS CORPORATION: BUSINESS OVERVIEW
  • TABLE 182 FUJIFILM HOLDINGS CORPORATION: PRODUCTS OFFERED
  • TABLE 183 FUJIFILM HOLDINGS CORPORATION: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–MARCH 2024
  • TABLE 184 CANON INC.: BUSINESS OVERVIEW
  • TABLE 185 CANON INC.: PRODUCTS OFFERED
  • TABLE 186 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.: BUSINESS OVERVIEW
  • TABLE 187 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.: PRODUCTS OFFERED
  • TABLE 188 ESAOTE SPA: BUSINESS OVERVIEW
  • TABLE 189 ESAOTE SPA: PRODUCTS OFFERED
  • TABLE 190 EIGEN HEALTH: COMPANY OVERVIEW
  • TABLE 191 EIGEN HEALTH: PRODUCTS OFFERED
LIST OF FIGURES
 
  • FIGURE 1 FUSION BIOPSY MARKET SEGMENTATION & REGIONAL SCOPE
  • FIGURE 2 FUSION BIOPSY MARKET: RESEARCH DESIGN
  • FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
  • FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 5 FUSION BIOPSY MARKET: REVENUE SHARE ANALYSIS
  • FIGURE 6 APPROACH BASED ON PATIENT POPULATION
  • FIGURE 7 APPROACH BASED ON NUMBER OF HOSPITALS
  • FIGURE 8 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
  • FIGURE 9 FUSION BIOPSY MARKET: TOP-DOWN APPROACH
  • FIGURE 10 DATA TRIANGULATION METHODOLOGY
  • FIGURE 11 FUSION BIOPSY MARKET, BY ROUTE TYPE, 2024 VS. 2029 (USD MILLION)
  • FIGURE 12 FUSION BIOPSY MARKET, BY PRODUCT, 2024 VS. 2029 (USD MILLION)
  • FIGURE 13 FUSION BIOPSY MARKET, BY APPLICATION, 2024 VS. 2029 (USD MILLION)
  • FIGURE 14 FUSION BIOPSY MARKET, BY END USER, 2024 VS. 2029 (USD MILLION)
  • FIGURE 15 GEOGRAPHICAL SNAPSHOT OF FUSION BIOPSY MARKET
  • FIGURE 16 INCREASING PREVALENCE OF PROSTATE CANCER TO DRIVE MARKET GROWTH
  • FIGURE 17 PROSTATE CANCER SEGMENT ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN MARKET IN 2023
  • FIGURE 18 CHINA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
  • FIGURE 19 ASIA PACIFIC TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD
  • FIGURE 20 DEVELOPING MARKETS TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD
  • FIGURE 21 FUSION BIOPSY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 22 VALUE CHAIN ANALYSIS OF FUSION BIOPSY MARKET: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASES
  • FIGURE 23 FUSION BIOPSY MARKET: SUPPLY CHAIN ANALYSIS
  • FIGURE 24 FUSION BIOPSY MARKET: ECOSYSTEM ANALYSIS
  • FIGURE 25 KEY PLAYERS IN FUSION BIOPSY MARKET ECOSYSTEM
  • FIGURE 26 FUSION BIOPSY MARKET: PORTER’S FIVE FORCES ANALYSIS
  • FIGURE 27 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF FUSION BIOPSY END USERS
  • FIGURE 28 KEY BUYING CRITERIA FOR FUSION BIOPSY END USERS
  • FIGURE 29 PATENT ANALYSIS FOR FUSION BIOPSY MARKET, JANUARY 2014–OCTOBER 2024
  • FIGURE 30 TRENDS AND DISRUPTIONS IMPACTING CUSTOMER BUSINESS IN FUSION BIOPSY MARKET
  • FIGURE 31 FUSION BIOPSY MARKET: INVESTMENT & FUNDING SCENARIO
  • FIGURE 32 NORTH AMERICA: FUSION BIOPSY MARKET SNAPSHOT
  • FIGURE 33 ASIA PACIFIC: FUSION BIOPSY MARKET SNAPSHOT
  • FIGURE 34 REVENUE SHARE ANALYSIS OF TOP PLAYERS IN FUSION BIOPSY MARKET, 2021–2023
  • FIGURE 35 MARKET SHARE ANALYSIS OF KEY PLAYERS IN FUSION BIOPSY MARKET (2023)
  • FIGURE 36 FUSION BIOPSY MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
  • FIGURE 37 FUSION BIOPSY MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023
  • FIGURE 38 EV/EBITDA OF KEY VENDORS, 2024
  • FIGURE 39 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND FIVE-YEAR STOCK BETA OF KEY VENDORS
  • FIGURE 40 FUSION BIOPSY MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
  • FIGURE 41 KONINKLIJKE PHILIPS N.V.: COMPANY SNAPSHOT (2023)
  • FIGURE 42 GE HEALTHCARE: COMPANY SNAPSHOT (2023)
  • FIGURE 43 FUJIFILM HOLDINGS CORPORATION: COMPANY SNAPSHOT (2024)
  • FIGURE 44 CANON INC.: COMPANY SNAPSHOT (2023)
  • FIGURE 45 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.: COMPANY SNAPSHOT (2022)

To determine the current size of the fusion biopsy market, this study engaged in four main activities. A comprehensive study was conducted using secondary research methods to gather data about the market, its parent market, and its peer markets. The next stage involved conducting primary research to confirm these conclusions, assumptions, and sizing with industry experts throughout the value chain. A combination of top-down and bottom-up methods was used to assess the overall market size. The market sizes of segments and subsegments were then estimated using data triangulation techniques and market breakdown.

The four steps involved in estimating the market size are

Secondary Research

Within the secondary data collection process, a range of secondary sources were reviewed so as to identify and gather data for this study, including regulatory bodies, databases (like D&B Hoovers, Bloomberg Business, and Factiva), white papers, certified publications, articles by well-known authors, annual reports, press releases, and investor presentations of companies.

Primary Research

In the primary research phase, a comprehensive approach was employed, involving the interviewing of several sources from both the supply and demand sides. The purpose of these interviews was to obtain the quantitative and qualitative information needed to put up this report. The main sources of information were industry experts from both core and related sectors, as well as preferred manufacturers, distributors, suppliers, pioneers in technology, and organizations involved in every aspect of this industry's value chain. A variety of primary respondents, including important industry stakeholders, subject-matter experts, C-level executives from crucial market companies, and industry advisers, were carefully questioned in-depth. The goal was to gather and validate important qualitative and quantitative insights and to conduct a thorough assessment of future possibilities.

A breakdown of the primary respondents is provided below:

Fusion Biopsy Market

Note 1: Others include sales, marketing, and product managers.

Note 2: Tiers of companies are defined based on their total revenue. As of 2023, Tier 1 = >USD 5 billion, Tier 2 = USD 500 million to USD 5 billion, and Tier 3 = < USD 500 million.

To know about the assumptions considered for the study, download the pdf brochure

COMPANY NAME DESIGNATION
GE Healthcare Business Manager
Koninklijke Philips N.V. Marketing Manger
FUJIFILM Corporation Consultant

Market Size Estimation

All major product providers offering various products and services were identified at the global/regional level. Revenue mapping was done for the major players and was extrapolated to arrive at the global market value of each type of segment. The market value of the fusion biopsy market was also split into various segments and subsegments at the region and country level based on:

  • Offering mapping of various manufacturers for each type in the fusion biopsy market at the regional and country-level
  • Relative adoption pattern of fusion biopsy market among key application segments at the regional and/or country-level
  • Detailed primary research to gather qualitative and quantitative information related to segments and subsegments at the regional and/or country level.
  • Detailed secondary research to gauge the prevailing market trends at the regional and/or country level

Both top-down and bottom-up approaches were used to estimate and validate the total size of fusion biopsy market.

Fusion Biopsy Market

Data Triangulation

After arriving at the overall market size applying the process mentioned above, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. By examining a number of variables and patterns from the supply and demand sides, the data was triangulated.

Market Definition

A fusion biopsy device is an advanced diagnostic tool that combines MRI and ultrasound imaging to create a detailed 3D visualization of the prostate. This device enables precise identification of abnormal tissue areas, enhancing the accuracy of biopsy procedures by guiding the needle directly to the targeted regions.

Stakeholders

  • Fusion biopsy system manufacturers and distributors
  • Hospitals
  • Ambulatory Surgery Centers
  • Cancer Centers
  • Surgeons and Medical Staff
  • Urologists
  • Selected Radiologists
  • Healthcare Providers
  • Market Research and Consulting Firms
  • Government Associations
  • Venture Capitalists and Investors

Report Objectives

  • To define, describe, segment, and forecast the fusion biopsy market by route type, product, application, end user, and region
  • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
  • To assess the fusion biopsy market with respect to Porter’s five forces, regulatory landscape, the value chain, the supply chain, ecosystem analysis, patent protection, pricing assessment, key stakeholders, and buying criteria
  • To analyze the micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall fusion biopsy market
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
  • To forecast the size of the market segments with respect to six regions, namely, North America, Europe, Asia Pacific, Latin America, the Middle East & Africa, and GCC Countries
  • To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies2
  • To track and analyze company developments such as product launches, collaborations, and other developments
  • To benchmark players within the market using the proprietary Company Evaluation Matrix framework, which analyzes market players on various parameters within the broad categories of business and product excellence

Previous Versions of this Report

Custom Market Research Services

We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements

Get 10% Free Customisation

Growth opportunities and latent adjacency in Fusion Biopsy Market

+1-888600-6441

Corporate Office Hours

+1-888600-6441

US/Can Toll Free

+44-800-368-9399

UK Office Hours

©2024 Marketsandmarkets Research Private Ltd. All Rights Reserved.

DMCA.com Protection Status